Effectiveness of the First Antiepileptic Drug in the Treatment of Pediatric Epilepsy

Pediatric Neurology

Volumn 41, Issue 1, 2009, Pages 22-26

  Ma, Ming Sheng ^a,b   Ding, Ying Xue ^a,b   Ying, Wang ^a   Fang, Fang ^a   Ding, Chang Hong ^a   Zou, Li Ping ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; TOPIRAMATE; VALPROIC ACID;

ARTICLE; ATTENTION DISTURBANCE; CHILD; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DECREASED APPETITE; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENURESIS; EPILEPSY; HEARING DISORDER; HEARING IMPAIRMENT; HUMAN; HYPERTHERMIA; INCIDENCE; INCREASED APPETITE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MEMORY; MEMORY DISORDER; MOOD CHANGE; MOOD DISORDER; NAUSEA; OBESITY; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SEIZURE; SIDE EFFECT; SOMNOLENCE; THERAPY EFFECT; TREATMENT RESPONSE; VOMITING;

ANTICONVULSANTS; CARBAMAZEPINE; CHILD; CHILD, PRESCHOOL; EPILEPSY; FRUCTOSE; HUMANS; RETROSPECTIVE STUDIES; SEIZURES; TREATMENT OUTCOME; VALPROIC ACID;

EID: 66349106166     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2009.01.010     Document Type: Article

References (26)

1. Bergqvist A.G. Idiopathic pediatric epilepsy syndromes. Continuum: Lifelong Learn Neurol 13 4 (2007) 106-120
2. ILAE Commission on Anti-Epileptic Drugs. Considerations on designing clinical trials to evaluate the place of new anti-epileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia 39 (1998) 799-803
3. Walker M.C., and Sander J.W. Difficulties in extrapolating from clinical trial data to clinical practice: the case of anti-epileptic drugs. Neurology 49 (1997) 333-337
4. Shinnar S., and Pellock J.M. The trials and tribulations of pediatric drug trials. Neurology 65 (2005) 1348-1349
5. ILAE Commission on Classification and Terminology. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 30 (1989) 389-399
6. ILAE Commission on Epidemiology and Prognosis. Guidelines for epidemiological studies on epilepsy. Epilepsia 34 (1993) 592-596
7. Berg A.T., Levy S.R., Testa F.M., and Shinnar S. Treatment of newly diagnosed pediatric epilepsy. Arch Pediatr Adolesc Med 153 (1999) 1267-1271
8. Tang-Wai R., Oskoui M., Webster R., and Shevell M. Outcomes in pediatric epilepsy: seeing through the fog. Pediatr Neurol 33 (2005) 244-250
9. Holland K.D., and Glauser T.A. Response to carbamazepine in children with newly diagnosed partial onset epilepsy. Neurology 69 (2007) 596-599
10. Kwan P., and Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 342 (2000) 314-319
11. Tishler D.M., Weinberg K.I., Hinton D.R., Barbaro N., Annett G.M., and Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 36 (1995) 1-6
12. Marchi N., Hallene K.L., Kight K.M., et al. Significance of MDR1 and multiple drug resistance in refractory human epileptic brain. BMC Med 2 (2004) 37
13. Abbott N.J., Khan E.U., Rollinson C.M., et al. Drug resistance in epilepsy: the role of the blood-brain barrier. Novartis Found Symp 243 (2002) 38-47 discussion 47-53, 180-5
14. Siddiqui A., Kerb R., Weale M.E., et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 348 (2003) 1442-1448
15. Anderson G.D. Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs. Ther Drug Monit 30 (2008) 173-180
16. Marson A.G., Al-Kharusi A.M., Alwaidh M., et al., SANAD Study Group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 369 (2007) 1000-1015
17. Marson A.G., Williamson P.R., Clough H., Hutton J.L., Chadwick D.W., and Epilepsy Monotherapy Trial Group. Carbamazepine versus valproate monotherapy for epilepsy: a meta-analysis. Epilepsia 43 (2002) 505-513
18. Marson A.G., Al-Kharusi A.M., Alwaidh M., et al., SANAD Study Group. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 369 (2007) 1016-1026
19. Nicolson A., Appleton R.E., Chadwick D.W., and Smith D.F. The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies. J Neurol Neurosurg Psychiatry 75 (2004) 75-79
20. Zou L.P., Lin Q., Qin J., Cai F.C., Liu Z.S., Mix E., and Topiramate Study Group. Evaluation of open-label topiramate as primary or adjunctive therapy in infantile spasms. Clin Neuropharmacol 31 (2008) 86-92
21. De Carolis P., Magnifico F., Pierangeli G., et al. Transient hypohidrosis induced by topiramate. Epilepsia 44 (2003) 974-976
22. Ziad e.K., Rahi A.C., Hamdan S.A., and Mikati M.A. Age, dose, and environmental temperature are risk factors for topiramate-related hyperthermia. Neurology 65 (2005) 1139-1140
23. Chung W.H., Hung S.I., Hong H.S., et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428 (2004) 486
24. García-Morales I., Sancho Rieger J., Gil-Nagel A., and Herranz Fernández J.L. Antiepileptic drugs: from scientific evidence to clinical practice. Neurologist 13 6 Suppl. 1 (2007) S20-S28
25. Karceski S., Morrell M., and Carpenter D. The Expert Consensus Guideline Series: treatment of epilepsy. Epilepsy Behav 2 6 (2001) A1-50
26. Guerrini R. Valproate as a mainstay of therapy for pediatric epilepsy. Paediatr Drugs 8 (2006) 113-129